Exploratory data show inavolisib benefits persist regardless of hyperglycemia in PIK3CA-mutated breast cancer, with ...
BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and ...
Please provide your email address to receive an email when new articles are posted on . Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations in ...
Safety was described as manageable for both doublet and triplet regimens with no new signals, supporting feasibility of comprehensive pathway targeting in metastatic disease. Company plans include an ...
Low-dose aspirin significantly reduced colorectal cancer recurrence in patients with PI3K pathway gene alterations, nearly halving recurrence rates over three years compared to placebo. The study ...
WNT pathway alterations in bevacizumab-treated early-onset colorectal cancer: An artificial intelligence–driven and disparity-aware precision oncology analysis. Longitudinal clinical validation of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results